XM does not provide services to residents of the United States of America.
F
F

Fresenius

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Fresenius And Cellular Origins Announce Development Agreement For Cell And Gene Therapy Manufacturing

BRIEF-Fresenius And Cellular Origins Announce Development Agreement For Cell And Gene Therapy Manufacturing Oct 16 (Reuters) - Fresenius SE & Co KGaA FREG.DE : FRESENIUS AND CELLULAR ORIGINS ANNOUNCE DEVELOPMENT AGREEMENT FOR CELL AND GENE THERAPY MANUFACTURING Further company coverage: FREG.DE (Gdansk Newsroom) ;))
F

Fresenius looking to boost output after hurricane damage at rival Baxter

UPDATE 4-Fresenius looking to boost output after hurricane damage at rival Baxter Updates Oct 8 story to add additional Fresenius comment, paragraph 4 FRANKFURT, Oct 9 (Reuters) - Germany's Fresenius FREG.DE said it was checking options to speed up the start of new production lines of medical equipment at a North Carolina facility to help mitigate potential shortages from hurricane damage to rival Baxter's BAX.N site in the same state.
F
F

Fresenius looking to boost production after hurricane damage at Baxter

Fresenius looking to boost production after hurricane damage at Baxter FRANKFURT, Oct 8 (Reuters) - Germany's Fresenius FREG.DE said it is checking options to start new infusion-solution production lines faster than planned at a North Carolina facility to help mitigate potential shortages due to the impact of Hurricane Helene on rival Baxter's North Cove site in the same state.
F

Fresenius: mAbxience And Teva Announce Second Strategic Global License Agreement For Biosimilar Oncology Treatment Candidate

BRIEF-Fresenius: mAbxience And Teva Announce Second Strategic Global License Agreement For Biosimilar Oncology Treatment Candidate Oct 3 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : MABXIENCE AND TEVA ANNOUNCE SECOND STRATEGIC GLOBAL LICENSE AGREEMENT FOR BIOSIMILAR ONCOLOGY TREATMENT CANDIDATE FRESENIUS SE - AGREEMENT COVERS GLOBAL MARKETS, INCLUD
F

FDA Says Identified Fresenius Kabi USA's Recall For Correction Of Ivenix Infusion System Lvp Software As Most Serious Type

BRIEF-FDA Says Identified Fresenius Kabi USA's Recall For Correction Of Ivenix Infusion System Lvp Software As Most Serious Type Oct 1 (Reuters) - FDA: FDA: FRESENIUS KABI USA, LLC, ISSUES CORRECTION FOR IVENIX INFUSION SYSTEM LVP SOFTWARE DUE TO ANOMALIES THAT MAY CAUSE DELAY/UNDERDOSAGE OF THERAPY FDA: IDENTIFIED FRESENIUS KABI USA'S RECALL FOR C
F

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.